Adult T-cell lymphoma/leukaemia refractory

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
5 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Corticosteroid 1 substance
Topoisomerase II inhibitor 1 substance
Alkylating agent 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Secura Bio Limited Commercial
    DUVELISIB
    2024-516605-23-00 9 countries 2025 n=94 Orphan
    Recruiting

Phase II

1 trial
  • Fondazione IRCCS Istituto Nazionale Dei Tumori Academic
    DEXAMETHASONE PHOSPHATE; ETOPOSIDE; IFOSFAMIDE; SELINEXOR
    2024-513295-18-00 1 country 2022 n=30
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Secura Bio Limited Commercial 1 Phase III 1
Fondazione IRCCS Istituto Nazionale Dei Tumori Academic 1 Phase II 0
New trials by year
2022
1
2025
1
← All indication landscapes